查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1842027

美国动物用药品市场：市场规模、份额和趋势分析（按产品、动物种类、给药途径和分销渠道划分），细分市场预测（2025-2033 年）

U.S. Veterinary Medicine Market Size, Share & Trends Analysis Report By Product, By Animal Type, By Route Of Administration, By Distribution Channel, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

美国动物用药品市场趋势：

据估计，2024 年美国动物用药品市场价值为 136.1 亿美元，预计到 2033 年将达到 260 亿美元，2025 年至 2033 年的复合年增长率为 7.6%。

市场成长主要受全球对动物性蛋白质需求不断增长的驱动，这推动了对更健康牲畜和高效疾病控制的需求。牲畜疾病发生率的上升进一步增加了对有效诊断和治疗方案的需求。此外，频繁的新产品发布和技术创新提高了先进兽医解决方案的可及性，而兽医学的持续进步则提高了动物保健的精准度和疗效。

由于新产品研发、业务拓展以及为引入创新技术而建立的策略联盟，市场正在不断演变。这些措施正在重塑市场需求和实践。例如，2025年2月，Align Capital Partners旗下的宠物健康平台Custom Veterinary Services (CVS)收购了Green Mountain Animal (GMA)，组成了一家名为CompletePet的综合性宠物健康产品公司。此次合併预计将提供各种定製配方的含药宠物饲料添加剂和健康产品，GMA位于佛蒙特州的工厂将继续支持其创新和供应链能力。

此外，宠物拟人化的趋势促使饲主更愿意在宠物照护上投入更多资金，因为他们越来越重视宠物的健康和福祉。兽医护理和宠物相关产品的支出，包括高檔食品、药品、预防性体检、疫苗接种、手术，甚至先进的治疗，都在不断增长。根据美国宠物用品协会预测，美国宠物支出将从2018年的905亿美元成长66%，到2024年达到约1506亿美元。虽然2018年至2020年间支出稳定成长，增幅为14.5%，但新冠疫情加速了这一趋势，导致2020年至2024年间支出激增45.4%。这主要是由于宠物饲养量的增加。

此外，FDA核准Zenrelia并于2024年9月在美国上市，将透过扩大犬类过敏性皮肤炎和异位性皮肤炎等常见但难以控制的疾病的治疗方法，在推动动物用药品市场成长方面发挥关键作用。皮肤病是宠物就诊最常见的原因之一，更有效治疗方法的推出将激发兽医和宠物主人对更佳治疗效果的强烈需求。与Apoquel等现有药物相比，Zenrelia的卓越疗效不仅将使其成为更多兽医和饲主饲主的首选治疗方案，还将提高新治疗方法的标准，并促进标靶治疗和精准医疗领域的研究与开发。

目录

第一章 分析方法和范围

第二章执行摘要

第三章美国动物用药品市场：驱动因素、趋势与范围

  • 市场联动展望
    • 母市场
    • 附随市场
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
    • 市场机会分析
    • 市场问题分析
  • 动物用药品市场：分析工具
    • 产业分析：波特五力分析
    • PESTEL分析
  • 定价分析
  • 法律规范
  • 产品平臺分析
  • 主要品种动物数量估算（2021-2024 年）

第四章：美国动物用药品市场：依产品分類的估算与趋势分析

  • 细分仪表板
  • 美国动物用药品市场：按产品分類的变化分析
  • 美国动物用药品市场规模及产品趋势分析（2021-2033）
  • 生技药品
    • 疫苗
    • 其他生技药品
  • 製药
    • 杀寄生虫剂
    • 抗感染药物
    • 消炎（药）
    • 止痛药
    • 其他的
  • 药用饲料添加剂
  • 其他的

第五章美国动物用药品市场：按动物类型分類的估算与趋势分析

  • 细分仪表板
  • 美国动物用药品市场：按动物类型分類的变化分析
  • 美国动物用药品市场规模及趋势分析（依动物种类划分）（2021-2033 年）
  • 生产动物
    • 家禽
    • 猪
    • 牛
    • 绵羊和山羊
    • 其他的
  • 伴侣动物
    • 狗
    • 猫
    • 马
    • 其他的

第六章：美国动物用药品市场：依给药途径分類的估算与趋势分析

  • 细分仪表板
  • 美国动物用药品市场：按给药途径分類的差异分析
  • 美国动物用药品市场规模及趋势分析（依给药途径划分）（2021-2033 年）
  • 口服
  • 注射
  • 外用药物
  • 其他的

第七章：美国动物用药品市场：按分销管道分類的估算和趋势分析

  • 细分仪表板
  • 美国动物用药品市场：按分销管道分類的波动分析
  • 美国动物用药品市场规模及趋势分析（按分销管道划分）（2021-2033 年）
    • 动物诊所和医院
    • 电子商务
    • 线下零售店
    • 其他的

第八章 竞争情势

  • 市场参与企业分类
  • 企业市场分析/热力图分析
  • 公司市占率分析（2024 年）
  • 公司简介
    • Boehringer Ingelheim International GmbH
    • Zoetis
    • Merck &Co., Inc.
    • Elanco
    • Dechra Pharmaceuticals PLC
    • Ceva Sante Animale
    • Bimeda Corporate
    • Biogenesis Bago
    • Phibro Animal Health Corporation
    • Virbac
  • 策略规划
    • 企业合併（M&A）
    • 商业伙伴关係与合作
    • 产品/服务发布
    • 其他的
  • 其他主要企业名单
Product Code: GVR-4-68040-197-8

U.S. Veterinary Medicine Market Trends:

The U.S. veterinary medicine market size was estimated at USD 13.61 billion in 2024 and is projected to reach USD 26.00 billion by 2033, growing at a CAGR of 7.6% from 2025 to 2033. The market growth is largely influenced by the rising global demand for animal protein, which increases the need for healthier livestock and efficient disease management. The growing incidence of animal diseases further amplifies the demand for effective diagnostic and treatment solutions. In addition, frequent product launches and innovations are enhancing the availability of advanced veterinary solutions, while continuous advancements in veterinary medicine are improving accuracy and outcomes in animal healthcare.

The market is continuously evolving due to research into novel product development, business expansion efforts, and strategic alliances to introduce innovative technologies. These efforts are reshaping market demand and practices. For instance, in February 2025, Align Capital Partners' pet health platform, Custom Veterinary Services (CVS), acquired Green Mountain Animal (GMA) to create a unified pet health products company called CompletePet. This merger is expected to offer a range of custom-formulated pet medicated feed additives and health products, with GMA's Vermont facility continuing to support innovation and supply chain capabilities.

Moreover, the growing trend of pet humanization has led pet owners to increasingly prioritize their pets' health and well-being, driving a willingness to spend significantly more on their care. People are spending more on veterinary care and pet-related products, including premium food, medications, preventive checkups, vaccinations, surgeries, and even advanced treatments. According to the American Pet Products Association, U.S. spending on pets rose from $90.5 billion in 2018 to around $150.6 billion in 2024, an increase of 66%. Between 2018 and 2020, spending grew steadily by 14.5%, but the COVID-19 pandemic accelerated the trend, with a 45.4% jump from 2020 to 2024, largely due to more people adopting pets.

In addition, the FDA approval and subsequent U.S. launch of Zenrelia in September 2024 are playing a pivotal role in driving the growth of the veterinary medicine market by broadening the availability of advanced therapies for widespread yet difficult-to-manage conditions such as allergic and atopic dermatitis in dogs. Skin disorders are among the most frequent reasons for veterinary visits, and introduction of more effective therapy creates strong demand from both veterinarians and pet owners seeking better outcomes. Zenrelia works better than existing drugs such as Apoquel, which not only makes more veterinarians and pet owners choose it but also raises the standard for new treatments, encouraging more research and development in targeted therapies and precision medicine.

U.S. Veterinary Medicine Market Report Segmentation

This report forecasts revenue growth provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. veterinary medicine market report based on product, animal type, route of administration, distribution channel:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Biologics
    • Vaccines
    • Modified/ Attenuated Live
    • Inactivated (Killed)
    • Other Vaccines
    • Other Biologics
  • Pharmaceuticals
    • Parasiticides
    • Anti-infectives
    • Anti-inflammatory
    • Analgesics
    • Others
  • Medicated Feed Additives
  • Others
  • Animal Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Production Animals
    • Poultry
    • Pigs
    • Cattle
    • Sheep & Goats
    • Others
  • Companion Animals
    • Dogs
    • Cats
    • Horses
    • Others
  • Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
  • Oral
  • Injectable
  • Topical
  • Other Routes
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Veterinary Hospitals & Clinics
  • E-commerce
  • Offline Retail Stores
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources
    • 1.3.4. Primary Research
    • 1.3.5. Details of Primary Research
    • 1.3.6. Data analysis model
  • 1.4. Information/Data Analysis
  • 1.5. Market Formulation & Visualization
  • 1.6. Data Validation & Publishing
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis
    • 1.7.2. Market: CAGR Calculation
  • 1.8. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Veterinary Medicine Market Variable Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market
    • 3.1.2. Ancillary Market
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing prevalence of chronic disease in pets
      • 3.2.1.2. Rising pet expenditure and pet humanization
      • 3.2.1.3. Technological advancements
      • 3.2.1.4. Strategic initiatives by key players
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Stringent regulatory process
      • 3.2.2.2. Increasing Influx Of Counterfeit Drugs.
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenge Analysis
  • 3.3. U.S. Veterinary Medicine Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitution
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Legal landscape
      • 3.3.2.3. Economic landscape
      • 3.3.2.4. Social landscape
      • 3.3.2.5. Technological landscape
      • 3.3.2.6. Environmental landscape
  • 3.4. Pricing Analysis
  • 3.5. Regulatory Framework
  • 3.6. Product Pipeline Analysis
  • 3.7. Estimated Animal Population by key Species, 2021 - 2024

Chapter 4. U.S. Veterinary Medicine Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Veterinary Medicine Market: Product Movement Analysis
  • 4.3. U.S. Veterinary Medicine Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
  • 4.4. Biologics
    • 4.4.1. Biologics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.2. Vaccines
      • 4.4.2.1. Vaccines Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.2.2. Modified/ Attenuated
        • 4.4.2.2.1. Modified/ Attenuated Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.2.3. Inactivated (Killed)
        • 4.4.2.3.1. Inactivated (Killed) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.2.4. Other Vaccines
        • 4.4.2.4.1. Other Vaccines Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.3. Other Biologics
      • 4.4.3.1. Other Biologics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Pharmaceuticals
    • 4.5.1. Pharmaceuticals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.2. Parasiticides
      • 4.5.2.1. Parasiticides Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.3. Anti-Infectives
      • 4.5.3.1. Anti-Infectives Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.4. Anti-Inflammatory
      • 4.5.4.1. Anti-Inflammatory Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.5. Analgesics
      • 4.5.5.1. Analgesics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.6. Others
      • 4.5.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Medicated Feed Additives
    • 4.6.1. Medicated Feed Additives Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Others

Chapter 5. U.S. Veterinary Medicine Market: Animal Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Veterinary Medicine Market: Animal Type Movement Analysis
  • 5.3. U.S. Veterinary Medicine Market Size & Trend Analysis, by Animal Type, 2021 to 2033 (USD Million)
  • 5.4. Production Animals
    • 5.4.1. Production Animals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.2. Poultry
      • 5.4.2.1. Poultry Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.3. Pigs
      • 5.4.3.1. Pigs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.4. Cattle
      • 5.4.4.1. Cattle Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.5. Sheep & Goat
      • 5.4.5.1. Sheep & goat Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.6. Others
      • 5.4.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Companion Animals
    • 5.5.1. Companion Animals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.2. Dogs
      • 5.5.2.1. Dogs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.3. Cats
      • 5.5.3.1. Cats Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.4. Horses
      • 5.5.4.1. Horses Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.5. Others
      • 5.5.5.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Veterinary Medicine Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Veterinary Medicine Market: Route of Administration Movement Analysis
  • 6.3. U.S. Veterinary Medicine Market Size & Trend Analysis, by Route of Administration, 2021 to 2033 (USD Million)
  • 6.4. Oral
    • 6.4.1. Oral Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.2. Injectable
    • 6.4.3. Injectable Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Topical
    • 6.4.5. Topical Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Others
    • 6.5.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Veterinary Medicine Market: By Distribution Channel Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. U.S. Veterinary Medicine Market: By End Use Movement Analysis
  • 7.3. U.S. Veterinary Medicine Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
    • 7.3.1. Veterinary Clinics & Hospitals
      • 7.3.1.1. Veterinary Clinics & Hospitals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.2. E-Commerce
      • 7.3.2.1. E-Commerce Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.3. Offline Retail Stores
      • 7.3.3.1. Offline Retail Stores Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.4. Others
      • 7.3.4.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Company Market Position Analysis/ Heat Map Analysis
  • 8.3. Company Market Share Analysis, 2024
  • 8.4. Company Profiles
    • 8.4.1. Boehringer Ingelheim International GmbH
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product/Service Benchmarking
      • 8.4.1.4. Strategic Initiatives
    • 8.4.2. Zoetis
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product/Service Benchmarking
      • 8.4.2.4. Strategic Initiatives
    • 8.4.3. Merck & Co., Inc.
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product/Service Benchmarking
      • 8.4.3.4. Strategic Initiatives
    • 8.4.4. Elanco
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product/Service Benchmarking
      • 8.4.4.4. Strategic Initiatives
    • 8.4.5. Dechra Pharmaceuticals PLC
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product/Service Benchmarking
      • 8.4.5.4. Strategic Initiatives
    • 8.4.6. Ceva Sante Animale
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product/Service Benchmarking
      • 8.4.6.4. Strategic Initiatives
    • 8.4.7. Bimeda Corporate
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product/Service Benchmarking
      • 8.4.7.4. Strategic Initiatives
    • 8.4.8. Biogenesis Bago
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product/Service Benchmarking
      • 8.4.8.4. Strategic Initiatives
    • 8.4.9. Phibro Animal Health Corporation
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product/Service Benchmarking
      • 8.4.9.4. Strategic Initiatives
    • 8.4.10. Virbac
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product/Service Benchmarking
      • 8.4.10.4. Strategic Initiatives
  • 8.5. Strategy Mapping
    • 8.5.1. Mergers & Acquisitions
    • 8.5.2. Partnerships & Collaborations
    • 8.5.3. Product/Service launch
    • 8.5.4. Others
  • 8.6. List of other key players

List of Tables

  • Table 1 List Of Secondary Sources
  • Table 2 U.S. Veterinary Medicine Market, By Product, 2021 - 2033 (USD Million)
  • Table 3 U.S. Veterinary Medicine Market, By Animal Type, 2021 - 2033 (USD Million)
  • Table 4 U.S. Veterinary Medicine Market, By Route of Administration, 2021 - 2033 (USD Million)
  • Table 5 U.S. Veterinary Medicine Market, By Distribution Channel, 2021 - 2033 (USD Million)
  • Table 6 Company Overview
  • Table 7 Product Benchmarking
  • Table 8 Financial Performance
  • Table 9 Strategic Initiatives

List of Figures

  • Fig. 1 Market Segmentation
  • Fig. 2 Market Research Process
  • Fig. 3 Information Procurement
  • Fig. 4 Primary Research Pattern
  • Fig. 5 Market Research Approaches
  • Fig. 6 Value Chain-Based Sizing & Forecasting
  • Fig. 7 QFD Modelling For Market Share Assessment
  • Fig. 8 Market Formulation & Validation
  • Fig. 9 U.S. Veterinary Medicine Market Revenue, 2021 - 2033 (USD Million)
  • Fig. 10 U.S. Veterinary Medicine Market Snapshot
  • Fig. 11 U.S. Veterinary Medicine Market Driver Impact
  • Fig. 12 U.S. Veterinary Medicine Market Restraint Impact
  • Fig. 13 U.S. Veterinary Medicine Product Key Takeaways (USD Million)
  • Fig. 14 U.S. Veterinary Medicine Market: Product, Market Share 2024 & 2033
  • Fig. 15 Biologics Market, 2021 - 2033 (USD Million)
  • Fig. 16 Vaccines Market, 2021 - 2033 (USD Million)
  • Fig. 17 Modified/ Attenuated Live Market, 2021 - 2033 (USD Million)
  • Fig. 18 Inactivated (Killed) Market, 2021 - 2033 (USD Million)
  • Fig. 19 Other Vaccines Market, 2021 - 2033 (USD Million)
  • Fig. 20 Other Biologics Market, 2021 - 2033 (USD Million)
  • Fig. 21 Medicated Feed Additives Market, 2021 - 2033 (USD Million)
  • Fig. 22 Pharmaceuticals Market, 2021 - 2033 (USD Million)
  • Fig. 23 Parasiticides Market, 2021 - 2033 (USD Million)
  • Fig. 24 Anti-infectives Market, 2021 - 2033 (USD Million)
  • Fig. 25 Anti-inflammatory Market, 2021 - 2033 (USD Million)
  • Fig. 26 Analgesic Market, 2021 - 2033 (USD Million)
  • Fig. 27 Other Vaccines Market, 2021 - 2033 (USD Million)
  • Fig. 28 U.S. Veterinary Medicine Animal Type Key Takeaways (USD Million)
  • Fig. 29 U.S. Veterinary Medicine Market: Animal Type, Market Share 2024 & 2033
  • Fig. 30 Production Animals Market, 2021 - 2033 (USD Million)
  • Fig. 31 Poultry Animals Market, 2021 - 2033 (USD Million)
  • Fig. 32 Pigs Animals Market, 2021 - 2033 (USD Million)
  • Fig. 33 Cattle Animals Market, 2021 - 2033 (USD Million)
  • Fig. 34 Sheep & Goat Animals Market, 2021 - 2033 (USD Million)
  • Fig. 35 Others Market, 2021 - 2033 (USD Million)
  • Fig. 36 Companion Animals Market, 2021 - 2033 (USD Million)
  • Fig. 37 Dogs Animals Market, 2021 - 2033 (USD Million)
  • Fig. 38 Cats Animals Market, 2021 - 2033 (USD Million)
  • Fig. 39 Horses Animals Market, 2021 - 2033 (USD Million)
  • Fig. 40 Others Market, 2021 - 2033 (USD Million)
  • Fig. 41 U.S. Veterinary Medicine Route of Administration Key Takeaways (USD Million)
  • Fig. 42 U.S. Veterinary Medicine Market: Route of Administration, Market Share 2024 & 2033
  • Fig. 43 Oral Market, 2021 - 2033 (USD Million)
  • Fig. 44 Injectable Market, 2021 - 2033 (USD Million)
  • Fig. 45 Topical Market, 2021 - 2033 (USD Million)
  • Fig. 46 Others Market, 2021 - 2033 (USD Million)
  • Fig. 47 U.S. Veterinary Medicine Market By End Use: Key Takeaways
  • Fig. 48 U.S. Veterinary Medicine Market By End Use, Market Share, 2024 & 2033
  • Fig. 49 Veterinary Clinics & Hospitals Market, 2021 - 2033 (USD Million)
  • Fig. 50 E-Commerce Market, 2021 - 2033 (USD Million)
  • Fig. 51 Offline Retail Stores Market, 2021 - 2033 (USD Million)
  • Fig. 52 Others Market, 2021 - 2033 (USD Million)
  • Fig. 53 Market Participant Categorization
  • Fig. 54 Market Share Of Key Market Players U.S. Veterinary Medicine Market